Myosana Therapeutics, Inc.

MyoGene Bio

This company develops gene-editing therapies to treat patients with Duchenne muscular dystrophy by restoring production of the dystrophin protein.

MyoGene Bio

This company develops gene-editing therapies to treat Duchenne muscular dystrophy and other muscle-wasting diseases for patients worldwide.

Bamboo Therapeutics

This company develops gene therapies for patients with rare neuromuscular and central nervous system diseases, including Duchenne muscular dystrophy.

MyoPax

This company develops muscle regeneration cell and gene therapies for patients with congenital malformations, trauma, hereditary dystrophies and muscle wasting disorders.

Exonics Therapeutics

The company develops gene editing therapies for patients with Duchenne muscular dystrophy and other genetic neuromuscular diseases.

Exonics

This company develops gene editing therapies for patients with Duchenne muscular dystrophy and other severe genetic neuromuscular diseases.

Phlox Therapeutics

This company develops RNA-based gene therapies to treat patients with rare genetic heart diseases, including cardiomyopathies and laminopathies.

Satellos

This company develops small molecule therapeutics to restore muscle regeneration for patients with Duchenne muscular dystrophy and other degenerative muscle diseases.